Novo Nordisk Poised to Rebound in Weight-Loss Drug Market

Novo Nordisk, the maker of the weight-loss drug Wegovy, is trying to catch up with its competitor Eli Lilly.

Novo Nordisk's stock price has fallen because Eli Lilly's drug, Zepbound, has taken the lead.

Novo is planning to launch a Wegovy pill to compete, aiming to regain market share.

They are also cutting jobs and suing companies selling copycat drugs.

Regulators are also increasing scrutiny of these copycat versions.

Despite these challenges, Novo is working on new drugs and aims to capitalize on the growing market for weight-loss medications.